In both animal experiments and studies of Parkinson’s disease patients, it has been found that L-dopa, the drug most commonly used in Parkinson’s disease, can lead to hyperhomocysteinemia (elevation of homocysteine levels in the blood). Therefore, when L-dopa is taken as part of micronutrient medicine (vital substances) to reduce homocysteine levels, care should be taken to ensure an adequate supply of vitamins B6, B12 and folic acid.
Within the framework of micronutrient medicine (vital substances), the following vital substances (micronutrients) are used for supportive therapy.
- In a multicenter study, coenzyme Q10 was able to slow the progression of functional disorders of Parkinson’s disease.
The above vital substance recommendations (micronutrients) were made with the help of medical experts. All statements are supported by scientific studies with high levels of evidence. For a therapy recommendation, only clinical studies with the highest degrees of evidence (grade 1a/1b and 2a/2b) were used, which due to their high significance prove the therapy recommendation. These data are updated at certain intervals.
* Vital nutrients (macro- and micronutrients) include vitamins, minerals, trace elements, essential amino acids, essential fatty acids, etc.
